Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396125 | 1.00 | CYP2D6 (0.40) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL396124 | 1.00 | CYP2D6 (0.40) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL2180265 | 0.94 | MAPT (0.41) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL1184772 | 0.94 | MAPT (0.41) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL27475233 | 0.88 | CYP2D6 (0.42) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL28632400 | 0.88 | CYP2D6 (0.42) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL28634513 | 0.88 | CYP2D6 (0.42) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL10137828 | 0.86 | CA1 (0.38) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL3406214 | 0.83 | CYP2D6 (0.31) | CYP2D6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL11193635 | 0.82 | HDAC8 (0.38) | CYP2D6HDAC8HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791538-A | Chemical synthesis method and application of vibrio cholerae O100 serotype O antigen oligosaccharide | 江南大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-104372039-A | Two-enzyme method for preparing rosuvastatin intermediates with branched chains | NANJING LANG EN BIOLOG SCIENCE & TECHNOLOGY CO LTD | 2015-02-25 | — | — | CN | disclosed |
| CN-102099330-B | Nitric oxide donating prostamides | NICOX SA | 2014-04-30 | — | — | CN | disclosed |
| EP-2274279-B1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8278454-B2 | Process for preparing tetrahydroquinoline derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2238143-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-2274279-A1 | NITRIC OXIDE DONATING PROSTAMIDES | Nicox S.A. (FR) | 2011-01-19 | — | — | EP | disclosed |
| US-20100311976-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-12-09 | — | — | US | disclosed |
| EP-2238143-A1 | NITRIC OXIDE DONOR COMPOUNDS | Nicox S.A. (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2009098113-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2009-08-13 | — | — | WO | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| CN-1348442-A | Novel sulfonamide compounds and uses thereof | MERCK & CO INC (US) | 2002-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR2, AGTR1, AGT | CYP2D6 284/4885HDAC8 2159/4885HDAC3 1227/4885 |
| US-20100311976-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | HNMT, PNMT, INMT | CYP2D6 385/4885HDAC8 3115/4885HDAC3 2317/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | CYP2D6 303/4885HDAC8 3388/4885HDAC3 2382/4885 |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | CYP2D6 950/4885HDAC8 1600/4885HDAC3 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.